R&D Trends

NIA/NIH grants $1.4M to Cognition Therapeutics' Alzheimer's program

Friday, May 23, 2014 02:35 PM

Cognition Therapeutics, an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, has announced that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer's disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH Alzheimer's Disease Drug Development Program. This cooperative agreement program for Alzheimer's disease translational research will provide Cognition Therapeutics with an estimated $1.4M in funding over four years to support critical drug development activities aimed at securing IND status for the company's first-in-class therapeutics.

More... »

WIRB Copernicus Group

BioRestorative Therapies, Pfizer ink research agreement

Friday, May 23, 2014 10:30 AM

BioRestorative Therapies, a life sciences company focused on adult stem cell-based therapies for various personal medical applications, has entered into a two-year collaborative research agreement with Pfizer to study human brown adipose tissue and cell lines.

More... »

CRF Health eCOA webinar series

Ligand licenses five programs to Viking Therapeutics

Friday, May 23, 2014 10:29 AM

Ligand Pharmaceuticals has licensed the rights to five programs to Viking Therapeutics, a clinical stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.

More... »

Novartis, Ophthotech ink agreement for Fovista

Wednesday, May 21, 2014 01:30 PM

Ophthotech, a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye, has entered into an ex-U.S. licensing and commercialization agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration (AMD). Ophthotech grants Novartis exclusive rights to commercialize Ophthotech's lead product candidate, Fovista, in markets outside the U.S. while Ophthotech retains sole rights to commercialize Fovista in the U.S.

More... »

Report: Value of U.S. health services M&A deals up 152%

Wednesday, May 21, 2014 01:29 PM

U.S. health services M&A total deal value rose 152% to $12.3 billion during the first quarter of 2014 compared to the same period in 2013, according to an analysis of M&A trends and outlook for the health services sector issued by PricewaterhouseCoopers U.S.

More... »

SBRI Healthcare launches new competition, $4.2M available to small businesses

Wednesday, May 21, 2014 01:27 PM

SBRI Healthcare, an NHS England funded initiative to develop innovative products and services that address unmet health needs, has launched the latest SBRI Healthcare competition with $4.2 million available to support small business.

More... »

Neurotrope, Stanford expand collaboration

Wednesday, May 21, 2014 01:25 PM

Neurotrope has signed an agreement with Stanford University to study and investigate certain analogs of bryostatin, referred to as "bryologs," as potential clinical candidates for the treatment of various neurological disorders.

More... »

Inovio Pharmaceuticals acquires DNA therapies from University of Pennsylvania

Wednesday, May 21, 2014 01:21 PM

Inovio Pharmaceuticals has acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer's disease and multiple sclerosis based on the academic research of Dr. Bin Wang, a professor at Fudan University's Shanghai Medical College, who worked closely with Dr. David Weiner at the University of Pennsylvania. Inovio will make clinical and regulatory milestone payments to the University.

More... »

Kymab receives $40M investment from Wellcome Trust, Gates Foundation

Monday, May 19, 2014 01:25 PM

The Bill & Melinda Gates Foundation and the Wellcome Trust each invested $20 million in Kymab, a monoclonal antibody biopharmaceutical company, to enable Kymab to maximize its Kymouse platform and advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies in areas of significant unmet medical need, including cancer and inflammation.

More... »

AstraZeneca, MRC Laboratory of Molecular Biology to launch joint research fund

Friday, May 16, 2014 12:47 PM

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology (MRC LMB) to fund a range of preclinical research projects aimed at better understanding the biology of disease.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs